GLG News by Abraxane Prescribers for Breast Cancer (US)
Articles with lock require a subscription to GLG News |
Request a free trial
August 14, 2008UK the model for US healthcare?
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for...
July 24, 2008EGFR and Non Small Cell Lung Cancer ( NSCLCa)
Analysis of: Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non–Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Recent BMS subanalysis indicate despite negative trial, EGFR indicates favorable outcome with platinum therapy EGFR will become target for frontline NSCLCa
July 10, 2008Cancer Care Is getting out of reach
Analysis of: Costly Cancer Drug Offers Hope, but Also a Dilemma | www.nytimes.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
The cost of medical care is increasing at an alarming rate The amount of money to support a physician's practice is going down at the same alarming rate especially in oncology
May 23, 2008Erbitux and Lung cancer
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Erbitux has had a few high level trials in Non small lung cancer So far there does not appear to be a contributuion to chemotherapy Maybe we are going about it the wrong way
May 19, 2008BRCA Mutations less risky than thought
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business
May 9, 2008ASA404 approach in treating lung cancer
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors
May 7, 2008Hedgehog pathwa drugs and chemotherapy
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE
April 21, 2008Why Xeloda can't eliminate 5FU
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight
April 16, 2008Non small cell lung cancer has little to be excited about
Analysis of: ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer | www.pipelinereview.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
Lilly will likely get front line approval for Alimta in non small cell lung cancer
Most patients with advanced disease never see a response to therapy
April 4, 2008Advantages of SenoRx Contura over Mammosite Breast Brachytherapy system.
Analysis of: A new player in the growing Breast Brachytherapy field | www.senorx.com
Author: Charles Bennett, Radiation Oncologist , Robert Boissoneault Oncology Institute
SenoRx has released the Contura system which provides a superior system when compared to the Mammosite Breast Brachytherapy System. These advantages include: 1. Better dosimetry, opening the door for more patients to be treated by avoiding the elimination of some patients due to skin spacing...
Page : 1 2 3 4 5 6 7 8 9 Next1 to 10 of 83
More GLG News in
Healthcare
Most Popular:
Source Article | Expert Analyses
ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease
www.medicalnewstoday.com
Expanding Circle of Inhibition: Small-Molecule Inhibitors of Bcl-2 as Anticancer Cell and Antiangiogenic Agents
jco.ascopubs.org
Healthways' Guidance Not So Healthy
www.forbes.com
Cell Genesys Ends Clinical Trials For Prostate Cancer Treatment
online.wsj.com
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
www.therapeuticsdaily.com
Azilect
September 2, 2008
Byetta Saves Lives
September 2, 2008
The Devil Is in the Details
September 1, 2008
Dangers of Methadone Usage
August 28, 2008
Healthways A Market Downturn and Results
August 26, 2008